ArticleDiscover oncology2025
Log odds of negative lymph nodes/T stage as a novel predictor of post-resection outcome in non-small cell lung cancer patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgery with systematic lymph node (LN) dissection remains the primary treatment for early-stage and locally advanced operable non-small-cell lung cancer (NSCLC). However, the effect of the log odds of negative lymph nodes/T stage (LONT) in NSCLC remains unclear. This study aims to evaluate the correlation between LONT and prognosis of stage I-III NSCLC patients who underwent resection.
methodsClinical data from patients who underwent NSCLC resection were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The log odds of negative LONT, defined as log(NLNs + 1)/T stage, was calculated for each patient. The nonlinear relationship between LONT and overall survival (OS) and lung cancer-specific survival (LCSS) was evaluated using the cubic spline smoothing technique and Cox regression. The optimal LONT cut-off point was determined using X-tile plots, and propensity score matching (PSM) was performed to minimize inter-group differences.
resultsLONT demonstrated a nonlinear positive relationship with both OS and LCSS. Based on X-tile plot-determined cut-off point of 0.60, participants were categorized into low (< 0.60) and high (≥ 0.60) LONT subgroups. Both before and after PSM, the high LONT group exhibited significantly better OS and LCSS compared to the low LONT group (both P < 0.001). Similar survival differences were observed in subgroup analyses based on lymph node status and TNM stage. LONT was an independent predictor of OS (HR: 0.78, 95% CI: 0.74-0.81, P < 0.001) and LCSS (HR: 0.75, 95% CI: 0.71-0.78, P < 0.001).
conclusionsLONT is a novel robust prognostic factor that could complement TNM staging system. A higher LONT is associated with better survival in stage I-III NSCLC patients who received resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.